Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB7839 with Rituximab after Auto-HCT for DLBCL
NCT02141451Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- May 2014
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of aderbasib in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Masonic Cancer Center. Primary endpoints: Dose Limiting Toxicity at 2 weeks and Progression Free Survival at 6 months. Started May 2014; status: completed.
02
Drugs
aderbasib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02141451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141451.